Drug Profile
Orbcel C - Orbsen Therapeutics
Alternative Names: Allogeneic umbilical cord-derived mesenchymal stromal cell therapy - Orbsen Therapeutics; Human umbilical cord derived CD362 enriched MSCs; ORBCEL C™; Orbcel-CLatest Information Update: 24 Jan 2023
Price :
$50
*
At a glance
- Originator Orbsen Therapeutics
- Developer Belfast Health and Social Care Trust; University of Birmingham
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Autoimmune hepatitis; Primary sclerosing cholangitis
- Phase I/II Adult respiratory distress syndrome
Most Recent Events
- 24 Jan 2023 Allogeneic umbilical cord-derived mesenchymal stromal cell therapy is still in phase I/II clinical trial in Adult respiratory distress syndrome (In adults, In adolescents, In the elderly) in United Kingdom
- 24 Jan 2023 Allogeneic umbilical cord-derived mesenchymal stromal cell therapy is still in phase II clinical trial in Autoimmune hepatitis and Primary sclerosing cholangitis in United Kingdom
- 13 May 2022 Efficacy and adverse events data from phase-I/II trial in Adult respiratory distress syndrome presented at the 118th International Conference of the American Thoracic Society (ATS-2022)